Traduction de «Source thérapeutique » (Français → Anglais) :

It is worth pointing out that these areas are often agricultural and have little opportunity to generate income because they are located in hilly and mountainous terrain, although they conceal beneath their surface very valuable mineral and spring waters with therapeutic properties.

In accordance with the results of the report, the Commission is to table proposals setting out an information strategy to ensure good-quality, objective, reliable and non-promotional information on medicinal products and other treatments and address the question of the information source's liability.

(3) Article 4(1)(e) of Directive 96/29/Euratom requires prior authorisation for, amongst other practices, the use of radioactive sources for industrial radiography or processing of products or research or the exposure of persons for medical treatment.

Mr Olsson too has already indicated in his report on rural policy how important this can be, for example, in order to give the switch-over to other sources of income, such as, agro-tourism, care farms, new energy sources, organic farming, local services and cultural manifestations a shot in the arm.

the time is not yet right to create embryos by means of somatic cell nuclear transfer (‘cloning for therapeutic purposes’) to meet the needs of cell therapy research, since there is a vast field of research still to be explored with the aid of other stocks of human stem cells, in other words those obtained from surplus embryos and foetal tissue and adult stem cells;

The key deliverables of the initiative include an assessment of the TPP cost-recovery initiative as it relates to the Treasury Board cost-recovery policy, and the public and private benefits that have derived from it; a thorough assessment of the current cost-recovery initiative costing model used by the TPP, including a comparison of other regulatory regimes and justifications, identification of any gaps in the current cost-recovery initiative, and the contribution of fees to the delivery of an efficient service; an evaluation of whether the cost-recovery initiative has had an impact on the TPP's performance, taking into consideration previous performance commitments, other jurisdictions' experience, options for improving feedback and/or ...[+++] communication mechanisms for stakeholders to foster transparency and accountability, and constraints that might limit my program's ability to manage the cost-recovery initiative and thereby the efficient operations of its programs; an assessment of the direct, indirect, and cumulative impacts of the cost-recovery initiative on therapeutic products industries, on consumers and the health care system, and on the TPP itself, and the development of a rigorous methodology and relevant data sources for a follow-up assessment of the impact of planned fees on the medical devices regulation area; and finally, a systematic review of lessons learned from other jurisdictions and options for operational and/or organizational alternatives and/or modifications to improve the management of the TPP cost recovery initiative.